News

Novo Nordisk promotes Wegovy for new customers as compounding ban takes effect
Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...
Wegovy maker cuts weight-loss drug's price to $199, but there's a catch
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.
Skye Bioscience, Inc.: Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic ...
Healthline3d
Zepbound More Effective for Weight Loss Than Wegovy, Eli Lilly Trial Shows
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Many Wall Street analysts think Novo Nordisk will make a solid rebound over the next 12 months. The company may have ...